COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma (JeRiCHO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02164500
Recruitment Status : Completed
First Posted : June 16, 2014
Last Update Posted : April 6, 2020
Information provided by (Responsible Party):
Dr. Bastian von Tresckow, University of Cologne

Brief Summary:

The Purpose of this trial is:

  • to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL
  • to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Condition or disease Intervention/treatment Phase
Recurrent Classical Hodgkin Lymphoma Drug: Ruxolitinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Study Start Date : October 2015
Actual Primary Completion Date : May 17, 2019
Actual Study Completion Date : May 17, 2019

Arm Intervention/treatment
Experimental: Ruxolitinib Drug: Ruxolitinib

Primary Outcome Measures :
  1. overall response rate [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • relapsed or refractory HL
  • ECOG <= 2,
  • no major organ dysfunction
  • written informed consent

Exclusion Criteria:

  • history of another primary malignancy ≤ 2 years
  • female patients who are pregnant or breast feeding
  • patients with a known history of HIV seropositivity
  • chronic active hepatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02164500

Layout table for location information
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany, 50924
Sponsors and Collaborators
University of Cologne
Additional Information:
Layout table for additonal information
Responsible Party: Dr. Bastian von Tresckow, Dr., University of Cologne Identifier: NCT02164500    
Other Study ID Numbers: JeRiCHO
First Posted: June 16, 2014    Key Record Dates
Last Update Posted: April 6, 2020
Last Verified: April 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases